Compare OSW & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSW | IMNM |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | Bahamas | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.5B |
| IPO Year | 2019 | 2020 |
| Metric | OSW | IMNM |
|---|---|---|
| Price | $26.60 | $25.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $27.00 | ★ $32.80 |
| AVG Volume (30 Days) | 821.4K | ★ 1.1M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $961,001,000.00 | $6,941,000.00 |
| Revenue This Year | $7.49 | N/A |
| Revenue Next Year | $8.52 | $1,127.34 |
| P/E Ratio | $59.91 | ★ N/A |
| Revenue Growth | ★ 7.37 | N/A |
| 52 Week Low | $19.06 | $8.67 |
| 52 Week High | $29.25 | $27.65 |
| Indicator | OSW | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 60.18 |
| Support Level | N/A | $19.28 |
| Resistance Level | N/A | $25.07 |
| Average True Range (ATR) | 0.00 | 0.99 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 0.00 | 85.39 |
OneSpaWorld Holdings Ltd is an operator of health and wellness centers onboard cruise ships and an operator of health and wellness centers at destination resorts all over the world. It offers a suite of premium health, fitness, beauty, and wellness services and products. The services provided by the company include body, salon, and skin care services and products, fitness classes and personal fitness training and pain management, detoxifying programs, and comprehensive body composition analyses among others. The company has only one single segment of Maritime and Destination Resorts.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.